CEACAM5 and adenocarcinoma: EGFR-mutated adenocarcinoma patients with either elevated CEA or Cyfra21-1 exhibited both shorter DFS and OS (CEA: 25.0 versus 46.4 months, log-rank χ2 = 21.977, P < 0.001 for DFS, Figure 1A; 48.6 months versus NR, log-rank χ2 = 16.315, P < 0.001 for OS, Figure 1B; Cyfra21-1: 24.0 versus 50.8 months, log-rank χ2 = 12.820, P < 0.001 for DFS, Figure 1C; 42.6 months versus NR, log-rank χ2 = 23.537, P < 0.001 for OS, Figure 1D).